

MEASURING ONCOLOGY NURSING-SENSITIVE PATIENT OUTCOMES: MEASUREMENT SUMMARY

NAUSEA AND VOMITING

Last Updated: June 2004

Verna Rhodes, RN, EDS, FAAN
Roxanne McDaniel, PhD, RN.

Tables of tools to measure oncology nursing-sensitive outcome: Nausea and Vomiting

Table A: Description of Tools

Name of Tool	Author/Year	Domains of Factors	# of Items	Scaling	Scoring	Language
Functional Living Index Emesis (FLIE)	Lindley et al; 1992	Effect of nausea and vomiting (NV) on physical activity, social and emotional function, and eating	18 9-nausea 9-vomiting	1—7, 7-point scale	A global score for NV is obtained by summing the items.	English French Japanese
Morrow Assessment of Nausea and Emesis (MANE)	Morrow, 1984	Anticipatory and Post-treatment nausea and vomiting •Frequency during and after treatment •Duration •Severity •Time when worse	16	Severity— 6-point scale Occurrence – yes or no Duration – number of hours	Occurrence, severity, and duration of pre- and post-treatment nausea and vomiting is assessed individually.	English Chinese (www.qolid.org/public/MANE.html) Portugese (14th international conference)
Index of Nausea, Vomiting, and Retching (INVR)	Rhodes & McDaniel, 1999	Nausea, vomiting, retching (NVR), and the components (frequency/amount, duration, severity, distress) of each symptom	8-total 5-occurrence 3-distress	5-point Likert Scale	A global score for NVR. Subscale scores for occurrence (five items) and distress (three items), and for individual symptoms	English Japanese Chinese Korean

Table B: Psychometric Properties of Tools

Name of Tool	Populations	Reliability	Validity	Sensitivity	Clinical Utility
Functional Living Index Emesis (FLIE)	<p>1- Patients with breast cancer (Bonnetterre et al., 1996)</p> <p>2- 133 patients with cancer receiving cyclophosphamide-based chemotherapy (Crucitt et al. 1996)</p> <p>3- 115 outpatients receiving either granisetron or ondansetron (Farley et al. 1997)</p> <p>4- 338 patients (primarily with lung cancer) receiving ondansetron with other antiemetics (Lebeau, 1997)</p> <p>5- 355 chemotherapy-naïve patients (Martin, 2003)</p> <p>6- Japanese patients with cancer (Satou, 2002)</p> <p>7- 66 radiotherapy patients (Sykes, 1997)</p>	<p>Cronbach's alpha 0.9</p> <p>Pearson item-scale correlations 0.40 to 0.82 pretreatment and 0.81 to 0.96 post-treatment</p>	<p>Factor Analysis (values not reported)</p> <p>Pearson correlation with nausea and vomiting -0.65 and 0.68</p> <p>Correlation with FLIC nausea factor 0.83</p>	<p>Differentiated between antiemetic groups (two items)</p> <p>Lower FLIE scores in patients receiving highly emetogenic chemotherapy (three items)</p> <p>Anticipate FLIE Japanese version will be useful in assessing change in quality of life due to nausea and vomiting (six items)</p>	<p>Ease of use</p> <p>Provides information about the effect of nausea and vomiting on functional status.</p> <p>Correlates with quality of life measures.</p>
Morrow Assessment of Nausea and Emesis (MANE)	<p>1- 133 patients with cancer receiving cyclophosphamide-based chemotherapy (Crucitt et al. 1996)</p> <p>2- 63 female patients with cancer (breast, GU, lung and lymphoma) receiving their first course of chemotherapy (Hickock et al., 2001)</p> <p>3- 72 adults aged 66–85, with solid tumors or hematological malignancies, undergoing antineoplastic therapy (Mantovani et al., 1996)</p> <p>4- 133 adults, with breast, lung, colorectal, and lymphoma (Martin et al, 2003)</p> <p>5- 71 chemotherapy-naïve Chinese women with breast cancer (Molassiotis et al., 2001)</p> <p>6- 1,413 outpatients in four community-based practices, data collected between 1987 and 1995 (Roscoe et al., 2000)</p> <p>7- 10 male and 10 female Portuguese patients with cancer (Alves-Guerreiro et al., 2003)</p>	<p>Test-retest reliability: 0.72 to 0.96 (Morrow, 1984)</p>	<p>Convergent validity 0.26 to 0.33;</p> <p>Divergent validity: - 0.04 to 0.08</p>	<p>Expectations of developing nausea positively correlated with anticipatory nausea ($r = 0.41$, $p = 0.001$) (two items).</p> <p>76% developed nausea within five days; 73% had delayed nausea during cycle 1 (two items).</p> <p>81.7% experienced acute nausea and 88.7% experienced delayed nausea; occurrence of nausea/vomiting at initial treatment strongly predictive of nausea/vomiting at later treatments (six items).</p> <p>Portuguese version reliability 0.83. Non-significant correlations between anticipatory and post-chemotherapy nausea and vomiting (seven items)</p>	<p>Primarily used with antiemetic studies.</p> <p>Long (> 24 hour) time frame</p>
Index of Nausea, Vomiting & Retching (INVR)	<p>1- 60 Japanese inpatients with cancer receiving chemotherapy (Arakawa, 1997).</p> <p>2- 17 women (59% Caucasian) with breast cancer</p>	<p>INVR: Spearman Correlation Total: 0.87</p>	<p>INVR - Spearman's correlation, $r = 0.87$</p>	<p>Decrease in nausea and vomiting in both groups (one item)</p>	<p>Ease of use. Provides information about nausea, vomiting, and retching</p>

Name of Tool	Populations	Reliability	Validity	Sensitivity	Clinical Utility
	who experienced nausea with prior chemotherapy. (Dibble et. al., 2000) 3- Adults > 65 (N = 102) and <65 (N = 25) receiving outpatient chemotherapy (Dodd et al., 1996). 4- 117 adult chemotherapy and 60 pregnant Chinese patients (Fu et al., 2002). 5- 20 children receiving chemotherapy and their parents (Lo & Haymann, 1999). 6- 159 adult patients: obstetrical (40), oncological (60), and medical/surgical (59) (Rhodes & McDaniel, 1999).	Individual items: 0.71 to 0.95 Equivalency: 79%–98% (p = 0.05) INV-2: Split-half reliability 0.90 Cronbach's Alpha 0.98	INV-2 – Spearman's correlation, r = 0.87	Differences existed between the two groups in regard to nausea experience (p < 0.01) and nausea intensity (two items) Significantly greater nausea, vomiting and retching in younger patients (three items) Parent and child ratings for total scores were highly correlated (five items).	total experience, occurrence, distress, and individual symptoms. 12-hour time frame Used with varied populations.

References related to instruments to measure outcome

Functional Living Index Emesis

Bonnetterre, J., Schraub, S., Lecomte, S., & Mercier, M. (1996). Quality of life as an outcome in breast cancer. *Pharmacoeconomics*, 9(Suppl. 2), 23–29.

Crucitt, M.A., Hyman, W., Grote, T., Tester, W., Madajewicz, S., Yee, S., et al. (1996). Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of healthrelated quality of life. *Clinical Therapeutics*, 18, 778–788.

Farley, P.A., Dempsey, C.L., Shillington, A.A., Kulis-Robitaille, C., Colgan, K., & Bernstein, G. (1997). Patients' self-reported functional status after granisetron or ondansetron therapy to prevent chemotherapy-induced nausea and vomiting at six cancer centers. *American Journal of Health-System Pharmacy*, 54, 2478–2482.

Lebeau, B., Depierre, A., Giovannini, M., Riviere, A., Kaluzinski, L., Votan B., et al. (1997). The efficacy of a combination of ondansetron, methylprednisolone and metopimazine in patients previously uncontrolled with a dual antiemetic treatment in cisplatin-based chemotherapy. The French Ondansetron Study Group. *Annals of Oncology*, 8, 887–892.

Martin, A.R., Carides, A.D., Pearson, J.D., Horgan, K., Elmer, M., Schmidt, C. et

al. (2003). Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. *European Journal of Cancer*, 39,1395–1401.

Satou, A., Yamazaki, T., Nukariya, N., Nakamachi, M., Shimada, K., Matsukawa, M., & Kurihara, M. (2002). Development of a Japanese version of the FLIE. *Gan to Kagaku Ryoho [Japanese Journal of Cancer and Chemotherapy]*, 29, 281–291.

Sykes, A.J., Kiltie, A.E., & Stewart, A.L. (1997). Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy. *Supportive Care in Cancer*, 5, 500–503.

Lindley, C.M., Hirsch, J.D., O'Neill, C.V., Transau, M.C., Gilbert, C.S., & Osterhaus, J.T.(1992). Quality of life consequences of chemotherapy-induced emesis. *Quality of Life Research*, 1, 331–340.

Morrow Assessment of Nausea

Alves-Guerreiro, J., Lowe-Strong, A.S., Walsh, D.M., Lopes, B.C., Costa, R., Rosado, R., et al. (2003). Development of a Portuguese version of the Morrow Assessment of Nausea and Emesis (MANE) Questionnaire: Moving physical therapy forward [Abstract]. *14th International World Confederation for Physical Therapy Congress*.

Crucitt, M.A., Hyman, W., Grote, T., Tester, W., Madajewicz, S., Yee, S., et al. (1996). Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life. *Clinical Therapeutics*, 18, 508–518.

Hickok, J.T., Roscoe, J.A., Morrow, G.R., Stern, R.M., Yang, B., Flynn, P.J., et al. (1999). Use of 5-HT₃ receptor antagonists to prevent nausea and emesis caused by chemotherapy for patients with breast carcinoma in community practice settings. *Cancer*, 86, 64–71.

Mantovani, G., Astará, G., Lampis, B., Bianchi, A., Curreli, L., Orru, W., et al. (1996). Evaluation by multidimensional instruments of health-related quality of life of elderly cancer patients undergoing three different "psychosocial" treatment approaches. A randomized clinical trial. *Supportive Care in Cancer*, 4, 129–140.

Martin, C.G., Rubenstein, E.B., Elting, L.S., Kim, Y.J., & Osoba, D. (2003). Measuring chemotherapy-induced nausea and emesis. *Cancer*, *98*, 645–655.

Molassiotis, A., Yung, H.P., Yam, B.M., Chan, F.Y., & Mok, T.S. (2002). The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients: A randomised controlled trial. *Supportive Care in Cancer*, *10*, 237–246.

Morrow, G. (1984). Assessment of nausea and vomiting: Past problems, current issues and suggestions for future research. *Cancer*, *53*, 2267-2278.

Roscoe, J.A., Morrow, G.R., Hickok, J.T., & Stern, R.M. (2000). Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. *Journal of Pain and Symptom Management*, *20*, 113–121.

Index of Nausea and Vomiting

Arakawa, S. (1997). Relaxation to reduce nausea, vomiting, and anxiety induced by chemotherapy in Japanese patients. *Cancer Nursing*, *20*, 342–349.

Dibble, S.L., Chapman, J., Mack, K.A., & Shih, A. (2000). Acupressure for nausea: Results of a pilot study. *Oncology Nursing Forum*, *27*, 41–47. [Oncology Nursing Forum](#)

Dodd, M.J., Onishi, K., Dibble, S.L., & Larson, P.J. (1996). Differences in nausea, vomiting, and retching between younger and older outpatients receiving cancer chemotherapy. *Cancer Nursing*, *19*, 155–161.

Fu, M.R., Rhodes, V., & Xu, B. (2002). The Chinese translation of the Index of Nausea, Vomiting, and Retching. *Cancer Nursing*, *25*, 134–140.

Lo, L.H. & Hayman, L.L. (1999). Parents associated with children in measuring acute and delayed nausea and vomiting. *Nursing and Health Sciences*, *1*, 155–161.

Rhodes, V.A. & McDaniel R.W. (1999). The Index of Nausea, Vomiting, and Retching: a new format of the Index of Nausea and Vomiting. *Oncology Nursing Forum*, *26*, 889–894. [Oncology Nursing Forum](#)